Yukihiro Umeda
Eiheiji, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications
Prognosis following the initiation of various immune checkpoint inhibitor therapies in TTF-1-negative non-small cell lung cancer.
Journal: Cancer treatment and research communications
Published: June 25, 2026
A Case of Enteric-Type Thymic Adenocarcinoma Treated with Lenvatinib.
Journal: Internal medicine (Tokyo, Japan)
Published: May 17, 2026
Survival outcomes in TTF-1 negative non-squamous non-small cell lung cancer (H-LINK 001).
Journal: Discover oncology
Published: February 14, 2026
Efficacy of Jiinshihoto on Depressive Symptoms in Patients With Pulmonary Mycobacterium avium-intracellulare Complex Disease not Receiving Standard Treatment.
Journal: Global advances in integrative medicine and health
Published: December 08, 2025
Successful treatment with erlotinib plus ramucirumab in a patient with non-small-cell lung cancer harboring EGFR exon 20 insertion mutation.
Journal: Anti-cancer drugs
Published: August 14, 2025
3'-deoxy-3'-18F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy.
Journal: EJNMMI research
Published: October 28, 2024
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.
Journal: Therapeutic advances in medical oncology
Published: October 16, 2024
Long-term Responders to Nanoparticle Albumin-bound Paclitaxel Following Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer.
Journal: Anticancer research
Published: September 02, 2024
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.
Journal: Therapeutic advances in medical oncology
Published: July 10, 2024
Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer.
Journal: Internal medicine (Tokyo, Japan)
Published: May 15, 2024
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Journal: Targeted oncology
Published: March 04, 2024
Last Updated: 09/26/2026